MENU
CTNM
AS OF
Feb 4, 04:52 PM (EDT)
Price
$14.78
Change
-$0.43 (-2.83%)
Capitalization
556.34M
29 days until earnings call
Intraday BUY SELL Signals
+Compare
CTNM
Stock ticker: NASDAQ
AS OF
Feb 4, 04:52 PM (EDT)
Price
$14.78
Change
-$0.43 (-2.83%)
Capitalization
556.34M

CTNM Contineum Therapeutics Forecast, Technical & Fundamental Analysis

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need... Show more

CTNM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CTNM with price predictions
Feb 03, 2026

CTNM in upward trend: 10-day moving average broke above 50-day moving average on January 23, 2026

The 10-day moving average for CTNM crossed bullishly above the 50-day moving average on January 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 14, 2026. You may want to consider a long position or call options on CTNM as a result. In of 30 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CTNM just turned positive on January 15, 2026. Looking at past instances where CTNM's MACD turned positive, the stock continued to rise in of 14 cases over the following month. The odds of a continued upward trend are .

CTNM moved above its 50-day moving average on January 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTNM advanced for three days, in of 94 cases, the price rose further within the following month. The odds of a continued upward trend are .

CTNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Aroon Indicator for CTNM entered a downward trend on January 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.083) is normal, around the industry mean (27.519). P/E Ratio (26.395) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (10.101) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CTNM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTNM is expected to report earnings to rise 44.44% to -64 cents per share on March 05

Contineum Therapeutics CTNM Stock Earnings Reports
Q4'25
Est.
$-0.65
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.34
Q1'25
Missed
by $0.20
Q4'24
Missed
by $0.11
The last earnings report on October 30 showed earnings per share of -44 cents, beating the estimate of -60 cents. With 8.82K shares outstanding, the current market capitalization sits at 556.34M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 333-5280
Employees
31
Web
https://www.contineum-tx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCCAX27.890.50
+1.83%
GMO Climate Change R6
EMOLX22.890.30
+1.33%
Lord Abbett Emerging Markets Equity F3
TVSVX21.090.21
+1.01%
Third Avenue Small Cap Value Investor
FCLCX47.18N/A
N/A
Fidelity Advisor Industrials C
SVBIX29.84-0.10
-0.33%
JHancock Balanced I

CTNM and Stocks

Correlation & Price change

A.I.dvisor tells us that CTNM and VYGR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTNM and VYGR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTNM
1D Price
Change %
CTNM100%
+5.77%
VYGR - CTNM
29%
Poorly correlated
-2.25%
TNGX - CTNM
28%
Poorly correlated
+5.11%
CCCC - CTNM
27%
Poorly correlated
+6.91%
MREO - CTNM
27%
Poorly correlated
-2.54%
SLN - CTNM
27%
Poorly correlated
-1.22%
More